Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Posttraumatic Stress Disorder
      • Long Covid
      • Cocaine Intoxication
      • Migraine
      • Depression
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Monkeypox
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-601 ER
      • TNX-1300
      • TNX-1900
      • TNX-4300
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-1850
      • TNX-801
    • Rare Disease
      • TNX-2900
    • Scientific Presentations
    • Expanded Access Policy
  • Medicines
  • Clinical Trials
  • News & Events
    • Tonix in the News
    • Press Releases
    • Investor Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Tonix in the News

Investors

Investors

  • Overview
  • News & Events
    • Tonix in the News
    • Press Releases
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Tonix in the News
  • Press Releases
  • IR Events
  • Email Alerts
  • Op-Eds
New England Journal of Medicine | Mar 30, 2020

Developing Covid-19 Vaccines at Pandemic Speed

Proactive | Sep 5, 2019

Tonix Pharmaceuticals doses first patient in Phase 1 trial to treat PTSD

Washington Examiner | Jan 1, 2019

Military-related PTSD: Our year to act

Washington Post | Jul 7, 2017

Scientists synthesize smallpox cousin in ominous breakthrough

Science | Jul 6, 2017

How Canadian researchers reconstituted an extinct poxvirus for $100,000 using mail-order DNA

The National Post | Mar 2, 2017

Canadian synthesizes a better smallpox vaccine - just in case terrorists bring the disease back

Reuters | May 19, 2016

Tonix Pharma PTSD drug shows promise in mid-stage study

Medscape | Nov 17, 2015

New Approach to Fibromyalgia Tackles Poor-Quality Sleep

PharmaVOICE | Nov 16, 2015

21st Century Cures Act

BioPharma Dive | Oct 8, 2015

An innovation challenge: Using pharma R&D as a tool for social change

Life Science Leader | Jul 1, 2015

Companies to Watch: Tonix Pharmaceuticals

Bioworld Today | May 14, 2015

Lead ‘tonic’ for Tonix targets fibromyalgia in phase III study

Fibromyalgia News Today | May 14, 2015

Tonix Pharmaceuticals Launches Phase 3 Clinical Trial To Evaluate Experimental Fibromyalgia Therapy

Pain.com | May 13, 2015

Sleep and Pain in Fibromyalgia

The Medicine Maker | May 5, 2015

The Big Leap from Academic to Entrepreneur

Clinical Pain Advisor | Mar 26, 2015

Better Sleep, Less Pain: Studying the Links

Daily News | Nov 11, 2014

Long battles remain for veterans suffering from PTSD

DDD Magazine | Aug 27, 2014

A ‘Second Revolution’ in Drug Discovery and Development

Life Science Leader | Jul 1, 2014

The Evolving Role Of Drug Mechanism Of Action In Drug Discovery And Development

Fibro & Fabulous | Jun 23, 2014

Interview with Dr. Seth Lederman CEO of Tonix Pharmaceuticals

rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Next Pagearrow_forward
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2023 Tonix Pharmaceuticals Holding Corp.